Oncotarget

Research Papers:

ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer

Juliane Strietz _, Stella S. Stepputtis, Bogdan-Tiberius Preca, Corinne Vannier, Mihee M. Kim, David J. Castro, Qingyan Au, Melanie Boerries, Hauke Busch, Pedro Aza-Blanc, Susanne Heynen-Genel, Peter Bronsert, Bernhard Kuster, Bernhard Kuster, Elmar Stickeler, Thomas Brabletz, Robert G. Oshima, Jochen Maurer

Metrics: PDF 374 views  |   HTML 319 views  |   ?  


Abstract

Juliane Strietz2,*, Stella S. Stepputtis2,3,*, Bogdan-Tiberius Preca2,3,*, Corinne Vannier2,3, Mihee M. Kim1, David J. Castro1, Qingyan Au1, Melanie Boerries3,5, Hauke Busch3,5, Pedro Aza-Blanc1, Susanne Heynen-Genel1, Peter Bronsert8,9,10, Bernhard Kuster6, Elmar Stickeler7, Thomas Brabletz4, Robert G. Oshima1,#, Jochen Maurer1,2,3,#

 1Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA

 2Department of Visceral Surgery, University Hospital Freiburg, German Cancer Consortium (DKTK), Freiburg, Germany

 3German Cancer Research Center (DKFZ), Heidelberg, Germany

 4Department of Experimental Medicine I, University of Erlangen-Nuernberg, Erlangen, Germany

 5Systems Biology of the Cellular Microenvironment at The DKFZ Partner Site Freiburg, German Cancer Consortium (DKTK), Institute of Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany

 6Technische Universitaet Muenchen, Partner Site of the German Cancer Consortium, Freising, Germany

 7Department of OBGYN, University Clinic Aachen (UKA), Aachen, Germany

 8Department of Surgical Pathology, University Medical Center Freiburg, Freiburg, Germany

 9German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany

10Institute of Pathology, University Medical Center Freiburg, Freiburg, Germany

*These authors have contributed equally and share first authorship

#These authors have contributed equally and share last authorship

Correspondence to:

Jochen Maurer, email: j.maurer@dkfz-heidelberg.de

Robert G. Oshima, email: rgoshima@SBPdiscovery.org

Keywords: ALPK1, ERN1, differentiation therapy, human bi-potential tumor-initiating cells, kinase knockdown

Received: March 21, 2016     Accepted: October 21, 2016     Published: November 04, 2016

ABSTRACT

Cancers are heterogeneous by nature. While traditional oncology screens commonly use a single endpoint of cell viability, altering the phenotype of tumor-initiating cells may reveal alternative targets that regulate cellular growth by processes other than apoptosis or cell division. We evaluated the impact of knocking down expression of 420 kinases in bi-lineage triple-negative breast cancer (TNBC) cells that express characteristics of both myoepithelial and luminal cells. Knockdown of ERN1 or ALPK1 induces bi-lineage MDA-MB-468 cells to lose the myoepithelial marker keratin 5 but not the luminal markers keratin 8 and GATA3. In addition, these cells exhibit increased β-casein production. These changes are associated with decreased proliferation and clonogenicity in spheroid cultures and anchorage-independent growth assays. Confirmation of these assays was completed in vivo, where ERN1- or ALPK1-deficient TNBC cells are less tumorigenic. Finally, treatment with K252a, a kinase inhibitor active on ERN1, similarly impairs anchorage-independent growth of multiple breast cancer cell lines. This study supports the strategy to identify new molecular targets for types of cancer driven by cells that retain some capacity for normal differentiation to a non-tumorigenic phenotype. ERN1 and ALPK1 are potential targets for therapeutic development.

Author Information

Juliane Strietz
Primary Contact  _

Stella S. Stepputtis

Bogdan-Tiberius Preca

Corinne Vannier

Mihee M. Kim

David J. Castro

Qingyan Au

Melanie Boerries

Hauke Busch

Pedro Aza-Blanc

Susanne Heynen-Genel

Peter Bronsert

Bernhard Kuster

Bernhard Kuster

Elmar Stickeler

Thomas Brabletz

Robert G. Oshima

Jochen Maurer


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13086